133 related articles for article (PubMed ID: 38582637)
1. Applicability and impact of the COMPASS trial in a Canadian population of patients with atherosclerotic disease.
Welsh RC; Gouda P; Dover D; Bainey KR; McAlister FA; Kaul P
Atherosclerosis; 2024 Jun; 393():117486. PubMed ID: 38582637
[TBL] [Abstract][Full Text] [Related]
2. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
[TBL] [Abstract][Full Text] [Related]
3. Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
Sheth MS; Yu B; Chu A; Porter J; Tam DY; Ferreira-Legere LE; Goodman SG; Farkouh ME; Ko DT; Abdel-Qadir H; Udell JA
J Am Heart Assoc; 2022 Dec; 11(24):e026553. PubMed ID: 36515238
[TBL] [Abstract][Full Text] [Related]
4. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.
Kataruka A; Mahtta D; Akeroyd JM; Hira RS; Kazi DS; Spertus JA; Bhatt DL; Petersen LA; Ballantyne CM; Virani SS
Cardiovasc Drugs Ther; 2021 Jun; 35(3):533-538. PubMed ID: 32880803
[TBL] [Abstract][Full Text] [Related]
5. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Darmon A; Elbez Y; Bhatt DL; Abtan J; Mas JL; Cacoub P; Montalescot G; Billaut-Laden I; Ducrocq G; Steg PG
Ann Cardiol Angeiol (Paris); 2020 Oct; 69(4):158-166. PubMed ID: 32778388
[TBL] [Abstract][Full Text] [Related]
8. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
Kruger PC; Guzik TJ; Eikelboom JW
Kardiol Pol; 2019 Aug; 77(7-8):661-669. PubMed ID: 31144674
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Wheeler M; Chan N; Eikelboom J
Future Cardiol; 2020 Nov; 16(6):597-611. PubMed ID: 32633570
[TBL] [Abstract][Full Text] [Related]
10. Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review.
Parascandolo E; Eisen A
Expert Rev Cardiovasc Ther; 2020 Sep; 18(9):577-585. PubMed ID: 32755422
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
Kaplovitch E; Eikelboom JW; Dyal L; Aboyans V; Abola MT; Verhamme P; Avezum A; Fox KAA; Berkowitz SD; Bangdiwala SI; Yusuf S; Anand SS
JAMA Cardiol; 2021 Jan; 6(1):21-29. PubMed ID: 32997098
[TBL] [Abstract][Full Text] [Related]
12. Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Coppens M; Weitz JI; Eikelboom JWA
Circ Res; 2019 Feb; 124(3):416-425. PubMed ID: 30702997
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
[TBL] [Abstract][Full Text] [Related]
14. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
Darmon A; Bhatt DL; Elbez Y; Aboyans V; Anand S; Bosch J; Branch KR; Connolly SJ; Dyal L; Eikelboom JW; Fox KAA; Keltai K; Probstfield J; Yusuf S; Abtan J; Sorbets E; Eagle KA; Ducrocq G; Steg PG
Eur Heart J; 2018 Mar; 39(9):750-757a. PubMed ID: 29186454
[TBL] [Abstract][Full Text] [Related]
15. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
Bhagirath VC; Eikelboom JW; Anand SS
Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
Lamy A; Eikelboom J; Sheth T; Connolly S; Bosch J; Fox KAA; Zhu J; Lonn E; Dagenais G; Widimsky P; Branch KRH; Bhatt DL; Zheng Z; Straka Z; Dagenais F; Kong Y; Marsden T; Lee SF; Copland I; Yusuf S
J Am Coll Cardiol; 2019 Jan; 73(2):121-130. PubMed ID: 30654882
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Anand SS; Bosch J; Eikelboom JW; Connolly SJ; Diaz R; Widimsky P; Aboyans V; Alings M; Kakkar AK; Keltai K; Maggioni AP; Lewis BS; Störk S; Zhu J; Lopez-Jaramillo P; O'Donnell M; Commerford PJ; Vinereanu D; Pogosova N; Ryden L; Fox KAA; Bhatt DL; Misselwitz F; Varigos JD; Vanassche T; Avezum AA; Chen E; Branch K; Leong DP; Bangdiwala SI; Hart RG; Yusuf S;
Lancet; 2018 Jan; 391(10117):219-229. PubMed ID: 29132880
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
[TBL] [Abstract][Full Text] [Related]
19. [Rivaroxaban with aspirin for the secondary prevention of cardiovascular events in Chinese patients with stable cardiovascular diseases: subgroup analysis of COMPASS].
Liang Y; Gong ZB; Lou KJ; Liu LS; Zhu J
Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Sep; 49(9):873-879. PubMed ID: 34530594
[No Abstract] [Full Text] [Related]
20. Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy.
Würtz M; Olesen KKW; Bhatt DL; Yusuf S; Muehlhofer E; Eikelboom JW; Maeng M
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):201-209. PubMed ID: 38453426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
